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With the development of recombinant DNA-technology, the DNA-derived drugs
represent a new therapeutic concept for human diseases (1). Two forms of recombinant
human granulocyte colony-stimulating factor (rHuG-CSF) are currently commercially
available for medical treatment, non-glycosylated protein (filgrastim) and glycosylated
protein lenograstim, with molecular mass of 19.6 kDa (2). Glycosylation has been repor-
ted to confer many advantages over non-glycosylation, including improvement of phy-
sical stability (3–6) and higher biological and pharmacological potency (5, 7, 8).
A common phenomenon of protein instability and a dominant degradation path-
way for therapeutic proteins is formation of aggregates (9). It is encountered routinely
during refolding, purification, sterilization, shipping and storage processes (10, 11). Ag-
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The stability of proteins is a subject of intense current in-
terest. Aggregation, as a dominant degradation pathway
for therapeutic proteins, may cause multiple adverse ef-
fects, including loss of efficacy and immunogenicity. In
the present study, the formation of aggregates in leno-
grastim under physiological conditions was monitored.
For this purpose, a simple and selective size-exclusion
high-performance liquid chromatography method for
detection and separation of aggregates from intact pro-
tein was developed. Sodium dodecyl sulphate-polyac-
rylamide gel electrophoresis was performed under redu-
cing and non-reducing conditions to determine the
nature of aggregate bond formation. Using both tech-
niques, the presence of a low aggregate content attached
via disulfide bonds was detected.
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gregation is rapidly emerging as a key issue underlying multiple deleterious effects for
protein-based therapeutics, including loss of efficacy and immunogenicity (10).
Size-exclusion high-performance liquid chromatography (SEC-HPLC) has been a
workhorse for detecting and quantifying protein aggregation (11). In conjunction with
other techniques, i.e., matrix assisted laser desorption/ionization-time of flight (MALDI-
-TOF), capillary isoelectric focusing (CIEF), sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE), the obtained results can be verified.
Many published studies for monitoring protein aggregation are available (12–15)
and some of them referred to determination of aggregates formation in filgrastim (10, 11,
16, 17). However, to our knowledge, the SEC-HPLC method for determination of intact
protein and detection of aggregates of lenograstim has not been reported in the litera-
ture.
The aim of our study was to assess the formation of aggregates in lenograstim un-
der physiological conditions and to develop a simple and selective SEC-HPLC method
for detection and separation of aggregates from intact protein, lenograstim. Also, we
performed SDS-PAGE under reducing and non-reducing conditions in order to get a
deeper insight into the nature of the aggregation mechanism.
EXPERIMENTAL
Chemicals and reagents
The lenograstim recombinant human granulocyte-colony stimulating factor deri-
ved from Chinese hamster ovary cells (rHuG-CSF) reference material was supplied by
Ray Biotech (USA) as sterile lyophilized powder.
All chemicals were of HPLC grade or analytical grade. Orthophosphoric acid and
sodium chloride were purchased from Alkaloid (Macedonia). All reagents for SDS-
-PAGE were obtained from Bio-Rad (USA). HPLC-grade water was used for all analyses.
SEC-HPLC
A Waters HPLC system (USA) was used, equipped with a Waters 600 pump, Waters
996 photodiode array detector and Millennium 32® software for data handling.
The experiments were carried out on size exclusion Fractogel® EMD BioSEC colu-
mn, superformance 600–16 mm (Merck, Germany). The HPLC system was operated iso-
cratically at ambient temperature using a mobile phase, which was composed of phos-
phoric acid (pH 2.5; 0.1 mol L–1) containing 150 mmol L–1 NaCl, run at a flow rate of
2 L min–1, and with UV detection at 215 nm. NaCl was added to the mobile phase to
avoid non-specific interactions between the proteins and the matrix. The mobile phase
was filtered using a 0.45-m filter and was degassed before use. Samples were injected
through a Rheodyne injector valve with 200-L sample loop. All determinations were
carried out in triplicate.
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SDS-PAGE
SDS-PAGE was carried out on a Bio-Rad Mini Protean Cell electrophoresis system
(USA). SDS-PAGE was performed under reducing and non-reducing conditions on 12%
separating gel and 4% stacking gel by the standard Laemmli procedure (18) in order to
separate both covalent and non-covalent aggregates from intact monomer. Under reduc-
ing conditions, a protein sample was prepared with Laemmli sample buffer and was
heated to near boiling for 10 minutes in the presence of reducing agent 2-mercaptoetha-
nol. Preparation of the protein sample under non-reducing conditions was done in the
same way except that no reducing agent was added. Following electrophoresis, due to
higher sensitivity, gels were stained with Silver stain Plus Kit (Bio-Rad, USA) according
to the vendor’s protocol.
Preparation of standard solution of lenograstim and sample solution
with induced aggregates
The standard solution of lenograstim (50 g mL–1) was prepared by dissolving it in
water.
Aggregation of lenograstim occurred under conditions that do not differ greatly
from physiological, in the absence of chemical denaturants. The sample solution was
prepared by dissolving lenograstim in phosphate buffered saline (pH 6.9) at the same
concentration as the standard solution (50 g mL–1) and was incubated 5 days at 37 °C
on a heating block.
RESULTS AND DISCUSION
Aggregation may compromise the stability as well as the biological activity of pro-
tein drugs. For protein drugs, the presence of aggregates of any type (soluble/insoluble,
covalent/noncovalent or reversible/irreversible) is typically considered to be undesirab-
le because aggregates may lead to loss of efficacy and may cause adverse effects in pa-
tients. However, the levels of soluble aggregates such as dimers and trimers, which are
acceptable, are not well defined (19).
From the analytical point of view, SEC-HPLC is one of the most sensitive and selec-
tive techniques that can separate and analyze aggregates.
In this study, the formation of aggregates in lenograstim under physiological condi-
tions (phosphate buffered saline pH 6.9 at 37 °C for 5 days) was monitored. For this pur-
pose, a SEC-HPLC method for detection and separation of aggregates from intact pro-
tein, lenograstim, was developed. Eluent of different pH values (2.5 and 7.0) was tested.
Satisfactory results were obtained under chromatographic conditions given in Experi-
mental. It was found that the use of SEC with low pH eluent provides a rapid means for
determining the existence and formation of aggregated species.
For the determination of aggregates, any peak from the chromatographic run that
was eluted before intact monomer was defined as aggregates.
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The chromatograms of standard solution (a) and sample solution (b) presented in
Fig. 1 have shown that under the proposed chromatographic conditions monomeric pro-
tein and aggregate are completely separated from each other in accordance with their
molecular masses. The presence of aggregate was indicated by the appearance of a dis-
tinct peak in the chromatogram at retention time shorter than the retention time of intact
monomer – lenograstim (Fig. 1b). The obtained retention times were approximately
58.24 min for intact protein and 17.82 min for aggregate.
Peak areas in the chromatograms (Fig. 1) were used to quantify the amounts of mo-
nomer and aggregate in incubated sample. The percent of monomeric protein present in
incubated sample was calculated by dividing the measured peak area by the peak area
for an unincubated sample of lenograstim (standard solution) and multiplying the result
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a)
b)
Fig. 1. SEC-HPLC chromatograms of lenograstim: a) standard solution of lenograstim
(50 g mL–1), unincubated (peak 1 – intact protein, monomer), b) sample solution of lenograstim
(50 g mL–1), incubated (peak 1 – intact protein, monomer; peak 2 – aggregate).
by 100. The percent of aggregate was calculated as the difference between the total pro-
tein present before incubation (standard solution) and the monomeric protein remaining
after incubation (sample solution), based on peak areas in the respective chromato-
grams. The obtained data shows that during incubation at 37 °C in phosphate buffered
saline pH 6.9, 93% of monomeric lenograstim remained after 5 days. The percent of ag-
gregate was only 7%.
Previous studies (10, 11) relating to the aggregation of filgrastim reported that un-
der the same aggregation conditions filgrastim was aggregated readily with 96% loss of
monomer.
Hence, the obtained results allow us to assume that lenograstim is more stable re-
garding aggregate formation than filgrastim. This data is in compliance with the previ-
ously reported statements of greater stability of glycosylated rHuG-CSF compared to
non-glycosylated rHuG-CSF (3–6).
Further work is being done in order to verify these results and to assess the stability
behaviour of lenograstim molecule.
SEC-HPLC proved to be useful and capable of monitoring high molecular mass ag-
gregates and monomeric proteins. But, this method provides information about the total
content of soluble aggregates. To get a deeper insight into the nature of the aggregation
mechanism of lenograstim, SDS-PAGE was performed, allowing differentiation between
covalently and non-covalently linked aggregates (under reducing and non-reducing
conditions). Non-covalent aggregation is caused by interactions between the exposed
hydrophobic residues of denatured protein molecules. Covalently linked protein aggre-
gates are due to chemical reactions, e.g., -elimination, disulfide exchange or transami-
dation (10).
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Fig. 2. Silver stained SDS-PAGE gels of lenograstim: a) reduced and b) non-reduced.
Lane 1 – molecular mass protein standard; lane 2 – standard solution of lenograstim,
unincubated; lane 3 – sample solution of lenograstim, incubated.
When the standard solution of lenograstim (unincubated sample) was analyzed by
SDS-PAGE under both reducing and non-reducing conditions, a heavy and distinct sin-
gle band with an approximate molecular mass of 20 kDa was observed (Fig. 2). Under
reducing conditions, the incubated sample solution of lenograstim showed only a single
distinct band corresponding to monomer (Fig. 2a). However, under non-reducing condi-
tions, two bands were observed: one distinct band assignable to monomer and another
faint band assignable to higher molecular mass aggregates (Fig. 2b). The lack of higher
molecular mass bands for the incubated sample solution of lenograstim under reducing
conditions demonstrates that if any soluble aggregates are attached covalently, the
bonds must be of disulfide type (15, 19).
A very weak high molecular mass band indicates the presence of trace amounts of
aggregate. The semi-quantitative analysis of band intensities by TotalLab software deli-
vered results that are in good agreement with SEC data. Both methods demonstrate a
low aggregate content after incubation at 37 °C for 5 days.
CONCLUSIONS
SEC-HPLC was used for monitoring aggregate formation in lenograstim and
SDS-PAGE confirmed the nature of aggregate bond formation. The presence of a low ag-
gregate content attached via disulfide bonds was detected. Further investigations are be-
ing performed to assess the stability behaviour of lenograstim molecule.
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S A @ E T A K
Prou~avanje stvaranja agregata rekombinantnog humanog granulocitnog
faktora stimulacije kolonija (rHuG-CSF), lenograstima, pomo}u
kromatografije isklju~enjem prema veli~ini i SDS-PAGE
JASMINA TONIC RIBARSKA, SUZANA TRAJKOVIC JOLEVSKA, ANA POCEVA PANOVSKA i ANETA DIMITROVSKA
Stabilnost proteina vrlo je aktualna problematika. Agregacija, kao dominantni put
razgradnje terapijskih proteina, mo`e uzrokovati razli~ite nuspojave, koje uklju~uju i
gubitak u~inkovitosti imunolo{kog sustava. U ovom radu pra}eno je stvaranje agregata
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u lenograstimu pod fiziolo{kim uvjetima. Razvijena je jednostavna i selektivna teku}in-
ska kromatografija visoke djelotvornost s isklju~enjem prema veli~ini za detekciju i raz-
dvajanje agregata od intaktnog proteina. Pomo}u natrij-dodecil sulfat poliakrilamidne
gel elektroforeze u reduciraju}im i nereduciraju}im uvjetima utvr|en je na~in stvaranja
agregata. Pomo}u obje tehnike mogu}e je detektirati prisutnost malih koli~ina agregata
koji su spojeni disulfidnim vezama.
Klju~ne rije~i: lenograstim, stvaranje agregata, teku}inska kromatografija visoke djelotvornosti is-
klju~enjem prema veli~ini, natrij-dodecil sulfat poliakrilamidna gel elektroforeza
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